Monday, July 13, 2026 See who Washington just made rich Go Pro · $40/mo →
Money Racket
Who Cashes In When Washington Moves
WHITE HOUSEFTC Forces Deere to Open Its Repair Tools — and Hands Independent Shops a Business ModeltodayTECHThe HBM Monopoly: How Federal Memory Standards Lock In Micron4 weeks agoCRYPTOVanguard's Crypto Pivot Signals Institutional Capitulation — Coinbase and Robinhood Are the Infrastructure WinnerstodayTECHThe Tariff Arbitrage: How Chip Import Duties Reshape the Foundry Map4 weeks agoWHITE HOUSETrump's Subpoenas of NYT Reporters Create Legal Overhang for News Publishers — and a Tailwind for First Amendment LitigatorstodayENERGYWhy Williams (WMB) Is Really a Policy Stock, Not a Pipeline Stock4 weeks agoENERGYFederal Nuclear Push Makes Centrus Energy's HALEU Monopoly More Valuable by the MonthtodayENERGYDOE Reopens the LNG Export Spigot: Cheniere Cashes In First, Kinder Morgan Collects the Toll4 weeks agoHEALTHCARE & FDAFDA Clears Casgevy for Toddlers with Sickle Cell — Vertex and CRISPR Therapeutics Get a Bigger MarkettodayTECHThe Chip Stack Below the Pentagon's AI Buildup4 weeks agoTECHThe White House's $2 Billion Quantum Bet Has Clear Stock Winners — and a Cryptography Deadline That Hurts LaggardstodayDEFENSEHII's Mission Technologies: The Unsexy Segment Where Navy Autonomy Dollars Actually Land First4 weeks agoDEFENSENATO's 3.5% GDP Spending Push Is a Multi-Year Order Book for Lockheed, RTX, and NorthroptodayTECHThe CHIPS Act Subsidy Ladder: Who Actually Receives the $39 Billion4 weeks agoENERGYFederal Proposal to Streamline Nuclear Environmental Reviews Cuts the Biggest Cost for SMR DeveloperstodayDEFENSEThe Refueling Line Nobody Prices Into BWXT4 weeks agoTRADE & TARIFFSDeepSeek's Custom Chip Gambit Is a Direct Threat to Nvidia's China Revenue — and a Warning for AMDtodayDEFENSEThe Law That Guarantees Matson a Buyer, No Matter the Price4 weeks agoHEALTHCARE & FDAMedicare Advantage Plans Are Set to Collect $13 Billion in Quality Bonuses — UnitedHealth and Humana Lead the QueuetodayENERGYThe Grid Hardening Bill Trade: How Federal Transmission Investment Lifts the Equipment Makers4 weeks agoCRYPTOThe SEC's 2026 Crypto Regulatory Agenda Is a Green Light for Coinbase and RobinhoodyesterdayTECHThe Export Control Squeeze: BIS Chip Rules Are Splitting the AI Hardware Market in Two4 weeks agoHEALTHCARE & FDATrump's Proposed Medicare Drug Savings Rule Puts PBMs in the Crosshairs — and Gives Pharma a Mixed SignalyesterdayDEFENSEWho Loses if the Navy's 355-Ship Goal Quietly Becomes a 'Right-Sized Fleet' Retreat4 weeks agoHEALTHCARE & FDAFDA Clears Casgevy for Toddlers — Vertex and CRISPR Therapeutics Just Doubled Their Addressable MarketyesterdayENERGYThe Only U.S. HALEU Cascade: How Centrus Became the Gatekeeper to the Advanced Reactor Boom4 weeks agoDEFENSENATO's Spending Surge Is Real and Getting Enforced — RTX, Lockheed, and AeroVironment Are the Direct BeneficiariesyesterdayDEFENSEMatson and the Jones Act: The Shipping Monopoly Washington Refuses to Touch4 weeks agoENERGYFederal Proposal to Streamline Nuclear Environmental Reviews Cuts the Clock for SMR DevelopersyesterdayDEFENSEThe Real Winner Behind the Navy's Shipbuilding "Get Well" Plan Is Second-Tier Suppliers, Not the Primes4 weeks agoENERGYCommonwealth LNG Permit Moves Forward — Cheniere and ConocoPhillips Are Watching CloselyyesterdayDEFENSELeidos: The Non-Obvious Beneficiary of Navy Digital and Sustainment Modernization4 weeks agoENERGYUSDA's Revamped Biorefinery Loan Guarantee Program Is a Quiet Tailwind for ADM and Renewable Chemical ProducersyesterdayENERGYThe Grid Reliability Mandate: FERC's Capacity Market Rules Are Writing Checks to Nuclear4 weeks agoTRADE & TARIFFSDeepSeek's Custom Chip Gambit Is a Direct Threat to Nvidia's China Revenue — and a Warning for AMDyesterdayENERGYThe Nuclear Restart Order: Only One Operator Has Actually Flipped the Switch4 weeks agoMARKETSFTC Forces John Deere to Open Its Repair Tools — Farmers Win, Deere's Software Moat Takes a HityesterdayDEFENSEAUKUS Pillar I Is a Slow-Burn Catalyst for GD and HII, Not a Pop4 weeks agoTRADE & TARIFFSMcCormick's $28M Tariff Refund Is a One-Time Cushion — the Underlying Cost Pressure Hasn't Gone Away2 days agoENERGYWashington Plugs AI Into Reactors: The Behind-the-Meter Nuclear Offtake Trade4 weeks agoTECHTrump Accelerates Post-Quantum Encryption Deadlines — and a Handful of Small-Cap Security Firms Are the Direct Beneficiaries2 days agoDEFENSEWhy BWXT Is Really a Policy Stock, Not an Industrial One3 weeks agoDEFENSENATO's 3.5% GDP Spending Push Is a Multi-Year Order Book for U.S. Defense Primes2 days agoDEFENSEHII vs. General Dynamics: Who Wins the Submarine Industrial Base Money3 weeks agoENERGYFederal Proposal to Streamline Nuclear Environmental Reviews Cuts Years Off the SMR Timeline2 days agoENERGYThe SMR Funding Funnel: How DOE's Loan Billions Flow to Small Modular Reactors3 weeks agoMARKETSFTC Forces John Deere to Open Its Repair Ecosystem — and the Aftermarket Parts Industry Wins2 days agoENERGYThe Uranium Supply Squeeze: How the Russian Import Ban Flows to Cameco and Centrus3 weeks agoHEALTHCARE & FDAMedicare Starts Covering Obesity Drugs — Novo Nordisk and Eli Lilly Just Got 67 Million New Potential Customers2 days agoDEFENSEPalantir's Real Moat Is the Data Rights Clause, Not the AI3 weeks agoENERGYCommonwealth LNG Permit Review Opens — Another Export Terminal in the Queue Benefits the Whole LNG Supply Chain2 days agoENERGYThe Nuclear Production Tax Credit Trade: Who Gets Paid to Keep Old Reactors Alive3 weeks agoTRADE & TARIFFSTariff Tailwinds Are Still Running for U.S. Metals — but the Easy Money in Steel and Aluminum May Already Be Priced2 days agoDEFENSEElbit's America Problem: What Buy American Rules Really Do to a Foreign Prime3 weeks agoTECHWhite House Quantum Summit and Accelerated PQC Deadlines Create a Spending Runway for IonQ and IBM3 days agoDEFENSECounter-Drone Spending Is the Quiet Twin of Drone Spending3 weeks agoHEALTHCARE & FDAMedicare Covering Obesity Drugs for the First Time Is a Direct Volume Catalyst for Novo Nordisk and Eli Lilly3 days agoENERGYSanctions Relief and the LNG Arbitrage: When State Department Decisions Move the Henry Hub3 weeks agoENERGYCommonwealth LNG Permit Review Opens a New Export Capacity Race — Cheniere Holds the Pole Position3 days agoDEFENSELeidos: The Losing Trade When "Efficiency" Becomes the Watchword in Washington3 weeks agoHEALTHCARE & FDAElevance Suing CMS Over Medicare Advantage Stars Is a Warning Sign for the Entire Managed Care Sector3 days agoENERGYThe Pipe Tax: How Section 232 Steel Tariffs Rewire U.S. Drilling Economics3 weeks agoDEFENSENATO's 3.5% GDP Spending Push Sends a Long-Term Revenue Signal to Raytheon, Lockheed, and Northrop3 days agoENERGYThe Tax Code Oil Patch: Who Gets Crushed If Washington Kills the IDC Deduction3 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Get a Bigger Market3 days agoDEFENSEThe Space-Based ISR Land Grab Nobody's Pricing In: Rocket Lab's Vertical Integration Bet3 weeks agoCRYPTOSEC's Pending Crypto Safe Harbor Rule Is the Clearest Regulatory Tailwind Coinbase Has Seen in Years3 days agoDEFENSEWho Actually Builds the Targets: The Overlooked Business Inside Kratos3 weeks agoENERGYU.S.-Iran Initial Deal Eases Sanctions Pressure — Oil Prices Face a Ceiling, E&P Stocks Feel It6 days agoENERGYThe Permit Logjam Is Breaking: Williams and Kinder Morgan Hold the Keys3 weeks agoDEFENSENATO's 'Report Card' Pressure Means Years of European Defense Spending — RTX and Lockheed Are the First Calls6 days agoDEFENSEAxon Is a Homeland-Security Policy Stock Wearing a Police-Gear Disguise3 weeks agoHEALTHCARE & FDAMedicare Starts Covering GLP-1 Obesity Drugs — Novo Nordisk and Eli Lilly Are the Direct Winners6 days agoDEFENSEGolden Dome Is a Sensor and Software Story Before It's a Missile Story3 weeks agoCRYPTOSEC Commissioner Signals Crypto Clarity Act Could Pass This Summer — Coinbase and Robinhood Are the Clearest Beneficiaries6 days agoENERGYThe Permian Methane Rule: Why Stricter EPA Standards Are a HAL and SLB Gift3 weeks agoTECHWhite House Lifts Export Controls on Anthropic's Advanced AI Models — Nvidia and AMD Are the Coattail Trade6 days agoENERGYThe BLM Calendar That Moves COP and OXY3 weeks agoENERGYMissouri Joins Federal Nuclear Fast-Track Program as State-Level Momentum Builds — Constellation, Vistra, and Oklo Are the Plays6 days agoDEFENSEMercury Systems: The Toll Booth Every Drone and Missile Program Has to Pass Through3 weeks agoHEALTHCARE & FDAFDA Clears Casgevy for Toddlers with Sickle Cell — Vertex and CRISPR Therapeutics Get a Bigger Market6 days agoDEFENSEKratos vs. AeroVironment: Which One Actually Wins the Cheap-Drone-Swarm Pivot3 weeks agoDEFENSEPentagon's $500M Counter-Drone Contract Is a Direct Payday for AeroVironmentlast weekENERGYLNG Export Licenses: How a FERC Approval Mints a Monopoly3 weeks agoCRYPTOCrypto Clarity Act Progress and SEC's ETF Rule Review Are the Two Biggest Near-Term Catalysts for Coinbase and Robinhoodlast weekDEFENSERTX's Two-Front Bet: Why Iran Tensions and NATO's 5% Pledge Hit the Same Ticker Differently3 weeks agoTECHTrump's Quantum Computing Executive Orders Create a Policy Tailwind for a Handful of Public Nameslast weekENERGYThe SPR Refill Trade: Who Gets Paid When Washington Buys Oil2 weeks agoDEFENSENATO's Spending Surge Is Real — and the US Defense Primes Are the Ones Getting Paidlast weekDEFENSEChina's Rare-Earth Squeeze Will Hit Defense Primes Unevenly2 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Children as Young as 2, Widening the Market for Vertex and CRISPR Therapeuticslast weekDEFENSEIron Dome and the FMS Pipeline: How Middle East Tensions Fund Missile Defense Primes2 weeks agoDEFENSEThe US-Iran Ceasefire Deal Pressures Oil Prices — and Reshuffles the Defense Tradelast weekDEFENSEThe Pentagon's AI Mandate: Why Defense Data Platforms Are Now a Weapons Program2 weeks agoHEALTHCARE & FDAFDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Get a Bigger Marketlast weekDEFENSELeidos Is the Quiet Beneficiary of Every "Modernize Federal IT" Executive Order2 weeks agoTRADE & TARIFFSNike's Tariff Refund Windfall Shows How Import-Heavy Brands Can Turn Trade Policy Into a Margin Storylast weekDEFENSESole-Source vs. Full-and-Open: The Slow Bleed in LMT's F-35 Sustainment Machine2 weeks agoHEALTHCARE & FDAFDA's BHT and ADA Reassessment Puts Food Additive Users on Notice — and Creates an Opening for Clean-Label Supplierslast weekDEFENSEThe Hypersonic Arms Race Has a Bottleneck — and Three Contractors Own It2 weeks agoENERGYMissouri Joins Federal Nuclear Fast-Track Program, Adding Momentum to the SMR Buildout Tradelast weekDEFENSEThe Loser Nobody Names: Export Controls Squeeze Boeing From Both Sides2 weeks agoDEFENSEPentagon's $500M Counter-Drone Contract Is a Direct Revenue Line for AeroVironmentlast weekDEFENSEThe Drone Proliferation Trade: Washington's Shift to Attritable Unmanned Systems Creates a Recurring Revenue Stream2 weeks agoTECHTrump's Post-Quantum Cryptography Executive Order Creates a Compliance Spending Mandate — and Clear Beneficiarieslast weekDEFENSENATO's 2% Mandate Is a Revenue Stream Disguised as an Alliance Obligation2 weeks agoDEFENSEHegseth's NATO Broadside and European Force Review Put Defense Primes in a Complicated Spotlast weekDEFENSEWho Actually Cashes In on 'Golden Dome': The Subcontractor Layer Behind LMT and RTX2 weeks agoENERGYThe US-Iran Initial Deal Puts Sanction Relief on the Table — and That's a Headwind for Oil Prices and E&P Stockslast weekDEFENSEHII Is a Congressional Appropriations Bet, Not a Navy Bet2 weeks agoENERGYWashington Is Rewriting Nuclear Radiation Safety Rules — Constellation, Vistra, and the SMR Crowd All Winlast weekDEFENSEWhen the Pentagon Classifies a Budget Line: The Black Budget Tradelast weekCRYPTOBitcoin Is Down 33% at Mid-Year and ETF Outflows Hit $4.3B in June — Coinbase and the Miners Are Feeling Itlast weekDEFENSEThe FMS Loophole: How State Department Sign-Offs Insulate Defense Primes From Shutdown Risklast weekTRADE & TARIFFSNike's Tariff Refunds Are a One-Time Boost, Not a Structural Fix — Here's What the Q4 Beat Actually Meanslast weekDEFENSESentinel vs. Columbia: The Nuclear Triad's Budget Is a Zero-Sum Gamelast weekWHITE HOUSETrump's Quantum Executive Order Sets a Hard Deadline — and Quantum Computing Stocks Are the Immediate Beneficiarylast weekDEFENSEThe Nuclear Triad Upgrade Cycle: Three Legs, Three Winners, Decades of Locked-In Spendinglast weekHEALTHCARE & FDAFDA Expands Casgevy to Toddlers — Vertex and CRISPR Therapeutics Just Got a Bigger Marketlast weekMARKETSSupreme Court Gives Trump FTC Firing Power — Antitrust Enforcement Just Got More Politicallast weekTECHCommerce Department's AI Model Export Controls Are the Next Nvidia Headwind — and AMD Isn't Immunelast weekTRADE & TARIFFSThe Tariff Refund Portal Is Open and Companies Are Cashing In — Nike and FedEx Are the Names to Watchlast weekHEALTHCARE & FDAMedicare Is Now Covering Wegovy — Novo Nordisk and Eli Lilly Just Got a Massive New Payerlast weekTRADE & TARIFFSTrump's Fertilizer Tariff Suspension Cuts Input Costs for Farmers — and Squeezes Domestic Producerslast weekHEALTHCARE & FDAMedicare Starts Covering GLP-1 Weight-Loss Drugs July 1 — Novo Nordisk and Eli Lilly Just Got 67 Million New Potential Customerslast weekDEFENSEWhy L3Harris Is Really a Policy Stock, Not a Hardware Stocklast weekDEFENSEHegseth's NATO Broadside and Europe Force Review Signal a Shift That Benefits U.S. Primes — at Europe's Expenselast weekDEFENSEThe F-35 Sustainment Lock-In: Why the Pentagon's Most Expensive Program Keeps Paying One Company Foreverlast weekDEFENSEPentagon's $500M Counter-Drone Contract Is a Direct Revenue Line for AeroVironment — and Pressure on Its Rivalslast weekHEALTHCARE & FDAFDA Expands Casgevy to Kids as Young as 2 — Vertex and CRISPR Therapeutics Just Got a Bigger Marketlast weekWHITE HOUSETrump's Quantum Executive Orders Set a 2030 Deadline — and a Spending Clock for IonQ, Rigetti, and the Cybersecurity Stacklast weekMARKETSThe Supreme Court Just Gave Trump Control Over the FTC — What That Means for M&A and Big Techlast weekCRYPTOBitcoin ETF Outflows Hit $4.3 Billion in June — Coinbase, MARA, and Strategy Are Carrying the Most Risklast weekTRADE & TARIFFSTariff Refunds Are Flowing — Nike and FedEx Are Among the First to See Real Moneylast weekWHITE HOUSETrump Suspends Fertilizer Tariffs — Farm Input Costs Drop and Ag Names Get a Quiet Tailwindlast weekDEFENSELockheed's $35B Interceptor Contract Is the Biggest Missile-Defense Payday in Years — Here's Who Else Gets Paidlast weekDEFENSEThe U.S.-Iran Ceasefire and $87.6B Pentagon Request Are Two Sides of the Same Defense Spending Boomlast weekENERGYMissouri Joins Federal Nuclear Fast-Track and a U.S. Uranium Project Clears Permitting — The Nuclear Supply Chain Is Movinglast week
1 free article left this week. A free account gets you 4 a week.Go Pro →
Energy

Federal Nuclear Push Makes Centrus Energy's HALEU Monopoly More Valuable by the Month

As SMR developers line up for NRC approvals and DOE support, the only U.S. company licensed to enrich high-assay low-enriched uranium sits at the center of the entire supply chain.

Image: Money Racket
By at Money Racket·Jul 13, 2026

The convergence of federal SMR permitting reform, NRC reviews at Palisades, and the broader nuclear-friendly policy environment under the Trump administration is accelerating demand for HALEU — the specialized fuel that most advanced reactor designs require. Centrus Energy (LEU) holds the only NRC license to produce HALEU in the United States, a position it reached with DOE funding.

Who cashes in: Centrus is the direct and unavoidable beneficiary. Every SMR developer that advances toward construction — Oklo, NuScale, TerraPower (private), X-energy (private) — needs HALEU, and there is currently no commercial-scale U.S. alternative to Centrus. The company's leverage to the nuclear buildout narrative is structural, not cyclical. As the federal government pushes to reduce dependence on Russian uranium enrichment (Russia's TENEX has historically been a major HALEU supplier), Centrus becomes a national security asset, not just a commercial one. Uranium Energy Corp (UEC) and Energy Fuels (UUUU) mine the uranium that eventually gets enriched — they benefit from rising demand but are one step removed from the HALEU bottleneck.

Every advanced reactor that gets approved needs HALEU. Right now, in the United States, that means it needs Centrus.

Who's exposed: The risk to Centrus is concentration: it has one facility, one product line, and one government customer relationship. Any DOE funding disruption or policy reversal hits the entire thesis. Centrus is also a small-cap with limited float, which means the stock can move violently on contract news in either direction. Russian enrichment capacity remains a competitive overhang — if sanctions on Russian nuclear fuel are relaxed, the urgency around domestic HALEU production diminishes.

Watch for DOE contract extensions or new HALEU purchase agreements — those are the revenue-confirming events. Also watch the NRC's Palisades SMR review timeline; faster approvals pull forward the date when HALEU demand becomes commercial rather than demonstration-scale.

Source: original report ↗

Free alerts

Free: catalyst alerts, straight to your inbox.

Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.

Free · weekly · unsubscribe anytime. Privacy.

Stay three moves ahead of every practice in your market.

Knowing it happened is table stakes. Money Racket Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.

Get the edge · $40/mo

Join the owners who run ahead of the industry. Cancel anytime, one click.

Discussion

    Leave a comment

    Comments are reviewed before they appear.
    Money Racket Pro

    By the time it's news, the money's already moved.

    The contract award, the executive order, the tariff cut — it mints winners before the financial press connects the dots. Pro gets you there first: what happened, who cashes in, and exactly what to watch — in a two-minute read.

    Go Pro · $40/mo The policy-to-profit brief. Cancel anytime.
    The pre-market brief · Mon–Sat, 7:45am ET Go Pro · $40/mo →